Ropes & Gray represented Viridian Therapeutics in an exclusive licensing and collaboration deal with Kissei Pharmaceutical to develop and market thyroid eye disease therapy veligrotug and VRDN-003 in Japan. The transaction was announced on July 30.
Under the agreement, Viridian will receive a $70 million upfront payment with potential to receive an additional $315 million in milestone payments as well as tiered royalties on net sales in Japan.
The Ropes & Gray team was led by life sciences licensing partner Hannah England and life sciences licensing associates Nicole Rohr and Ryan Kramer and included tax partner David Saltzman..
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.